- Record: found
- Abstract: found
- Article: not found
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.
Lorena Carballo-Folgoso
1 ,
Rut Álvarez-Velasco
2 ,
Rebeca Lorca
2
,
3 ,
Andrés Castaño-García
1 ,
Javier Cuevas
2 ,
María Luisa González-Diéguez
1 ,
María Martín
2 ,
Carmen Álvarez-Navascués
1 ,
Valle Cadahía
1 ,
César Morís
2
,
3
,
4 ,
Manuel Rodríguez
1
,
3
,
4 ,
María Varela
1
,
3
,
4
,
5
September 2021
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The effectiveness of systemic treatment in advanced hepatocellular carcinoma (HCC) depends on the selection of patients, management of cirrhosis complications and expertise to treat adverse events. The aims of the study are to assess the frequency and management of cardiovascular events in HCC patients treated with sorafenib (SOR) and to create a scale to predict the onset of major adverse cardiovascular events (MACE).